Company Overview and News
Investors in Immunomedics, Inc. (IMMU - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17, 2017 $7.00 Put had some of the highest implied volatility of all equity options today. (39-1)
Immunomedics, Inc. (NASDAQ:IMMU) has 166 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 130,271,376 shares. Largest shareholders include venBio Select Advisor LLC, Seattle Genetics Inc /wa, Orbimed Advisors Llc, BlackRock Inc., and Acuta Capital Partners, Llc. (62-0)
Immunomedics, Inc. (IMMU - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $1.15 to $1.31 in the past one month time frame. (29-0)
Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Immunomedics Incorporated First Quarter Fiscal 2018 Results Conference Call. As a reminder, this call is being recorded. Today is Thursday, November 9, 2017. (58-0)
Investors in Immunomedics, Inc. (IMMU - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 19, 2018 $4 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (78-0)
Palo Alto Investors, LLC has disclosed 38 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 1,752,860,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Palo Alto Investors, LLC's top holdings are Clovis Oncology, Inc. (NASDAQ:CLVS) , ABIOMED, Inc. (NASDAQ:ABMD) , United Therapeutics Corp. (NASDAQ:UTHR) , BioMarin Pharmaceutical, Inc. (143-1)
venBio Select Advisor LLC has disclosed 45 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 495,012,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). venBio Select Advisor LLC's top holdings are Immunomedics, Inc. (NASDAQ:IMMU) , Kite Pharma, Inc. (NASDAQ:KITE) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) , TESARO, Inc. (118-3)
Avisol Capital Partners, managed by Drs Udaya Maiya and Ashok Dutta, is writing a daily scoop of all sorts of news, catalysts, ratings, and other actionable details for its watch list stocks (and the rest of the healthcare universe). The watch list is available to Total Pharma Tracker subscribers. Some sections, like the catalyst data, abstract selections, AdComm coverages, Buy/Sell summaries etc are also available to subscribers only. (89-2)
We believe that IMMU-132 will not be granted accelerated approval, and IMMU’s mandatory Phase 3 trial will fail, burning through IMMU’s current cash position. Amazingly, IMMU is approaching highest valuation in its entire existence. (142-3)
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (4-0)
Investors in Immunomedics, Inc. (IMMU - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the August 18th, 2017 $13 Call had some of the highest implied volatility of all equity options today.
Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Immunomedics Inc. Fourth Quarter and Fiscal Year 2017 Results Conference Call. As a reminder, this call is being recorded. Today is Wednesday, August 16, 2017.
* Immunomedics Inc - cash, cash equivalents, and marketable securities totaled $154.9 million as of june 30, 2017
The stock selection screen leverages academic models of the Altman Z-score, Ohlson O-score, and the Beneish M-score.
* Files for 34.8 million shares of co's common stock by the selling stockholders - sec filing
Stock Research Report
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The company's advanced proprietary technologies allow it to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of six clinical-stage product candidates.
The company believe that each of its antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with chemotherapeutics, therapeutic radioisotopes (radiolabeled), cytokines or other toxins to create unique and potentially more effective treatment options. The attachment of various compounds to antibodies is intended to allow the delivery of these therapeutic agents to tumor sites with better specificity than conventional chemothe...
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton